🚨Publication Alert 🚨 Check out this week's publication in Clinical and Translational science from the ASCPT Journal Family.
📃Read it here: https://hubs.la/Q01xzwSH0
Obesity is a prevalent childhood condition and the degree of adiposity appears to be an important covariate in the pharmacokinetic (PK) studies of many drugs. Understanding the impact of obesity on the disposition of drugs in children by quantification of the covariate effect of body fat percentage (BF%) on PK parameters in children is an urgent priority since BF% has seldom been measured in PK trials in children.
This study, carried out by a group of expert pharmacometricians including Huali Wu — director of pharmacometrics consulting at Amador — explores the relationships between BF% and drug PK values in children. The methodology applied identifies the sources of variability in drug clearance and distribution volumes and acknowledges that accurate estimation of the degree of adiposity will provide a potentially valuable covariate in clinical PK studies.
The authors advise that clinical PK studies should include adequate representation of children with obesity and include estimates of the degree of adiposity in these analyses, concluding that to quantify the effect of adiposity on drug PK in children with obesity, BF% can be estimated from one of several anthropometric equations, or even more easily from the estimates of BF% based on obesity stage.
This data may contribute to improving the safety and efficacy of drug therapy in all children and adolescents with obesity.